Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
Company Information
About this company
Key people
David A. Ricks
Chairman of the Board, President, Chief Executive Officer
Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Eric Dozier
Executive Vice President, Chief People Officer
Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Daniel M. Skovronsky
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
Anat Hakim
Executive Vice President, General Counsel, Secretary
Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Melissa Seymour
Executive Vice President - Global Quality
Jacob S. Van Naarden
Executive Vice President, President - Lilly Oncology
Juan Ricardo Luciano
Lead Independent Director
Raul Alvarez
Independent Director
Katherine Baicker
Independent Director
Carolyn R. Bertozzi
Independent Director
J. Erik Fyrwald
Independent Director
Click to see more
Key facts
- Shares in issue945.75m
- EPICLLY
- ISINUS5324571083
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$984.63bn
- Employees47,000
- ExchangeNew York Stock Exchange
- IndexS&P 500, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.